Cargando…

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis

INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, f...

Descripción completa

Detalles Bibliográficos
Autores principales: Conticini, Edoardo, Sota, Jurgen, Falsetti, Paolo, Baldi, Caterina, Bardelli, Marco, Bellisai, Francesca, Tosi, Gian Marco, Frediani, Bruno, Cantarini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537685/
https://www.ncbi.nlm.nih.gov/pubmed/33061825
http://dx.doi.org/10.1155/2020/3203241
_version_ 1783590714519584768
author Conticini, Edoardo
Sota, Jurgen
Falsetti, Paolo
Baldi, Caterina
Bardelli, Marco
Bellisai, Francesca
Tosi, Gian Marco
Frediani, Bruno
Cantarini, Luca
author_facet Conticini, Edoardo
Sota, Jurgen
Falsetti, Paolo
Baldi, Caterina
Bardelli, Marco
Bellisai, Francesca
Tosi, Gian Marco
Frediani, Bruno
Cantarini, Luca
author_sort Conticini, Edoardo
collection PubMed
description INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, few data are available on the role of different imaging techniques in monitoring GCA activity and response to treatment. We report herein a cohort of GCA patients treated with TCZ and followed up with multimodal imaging. Patients and Methods. We collected clinical, laboratory, and imaging data of 11 GCA patients treated with TCZ 162 mg subcutaneously every week. Disease activity was assessed at baseline and within 12 months from the start of treatment using different imaging techniques such as color Doppler ultrasonography (CDUS), magnetic resonance imaging/angiography (MRI/MRA), computed tomography angiography (CTA), and/or positron emission tomography (PET). RESULTS: Four patients were affected by cranial and 7 by LV-GCA. All patients were treated with oral glucocorticoids (GCs) (mean dose 55.68 mg ± 8.19 of prednisone or equivalent) in combination with TCZ. Treatment was preceded in 5 cases by 3 intravenous boluses of 1000 mg methylprednisolone. A significant decrease of the mean dose of oral GCs was observed between baseline and the last follow-up visit (4.65 ± 3.69 mg) (p = 0.003). TCZ treatment significantly decreased erythrocyte sedimentation rate (p < 0.01) and CRP levels (p < 0.01). At follow-up (mean 8.18 ± 3.63 months), all patients were in clinical and serological remission. Moreover, PET, CDUS, MRI/MRA, and CTA did not show any LVV finding. CONCLUSIONS: Our study highlights TCZ efficacy in inducing GCA remission and its steroid-sparing effect. We highlighted a reliability of imaging procedures in the evaluation of disease activity and treatment response. A close disease monitoring with imaging techniques should be taken into account in GCA patients during TCZ treatment.
format Online
Article
Text
id pubmed-7537685
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75376852020-10-13 The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis Conticini, Edoardo Sota, Jurgen Falsetti, Paolo Baldi, Caterina Bardelli, Marco Bellisai, Francesca Tosi, Gian Marco Frediani, Bruno Cantarini, Luca Mediators Inflamm Clinical Study INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, few data are available on the role of different imaging techniques in monitoring GCA activity and response to treatment. We report herein a cohort of GCA patients treated with TCZ and followed up with multimodal imaging. Patients and Methods. We collected clinical, laboratory, and imaging data of 11 GCA patients treated with TCZ 162 mg subcutaneously every week. Disease activity was assessed at baseline and within 12 months from the start of treatment using different imaging techniques such as color Doppler ultrasonography (CDUS), magnetic resonance imaging/angiography (MRI/MRA), computed tomography angiography (CTA), and/or positron emission tomography (PET). RESULTS: Four patients were affected by cranial and 7 by LV-GCA. All patients were treated with oral glucocorticoids (GCs) (mean dose 55.68 mg ± 8.19 of prednisone or equivalent) in combination with TCZ. Treatment was preceded in 5 cases by 3 intravenous boluses of 1000 mg methylprednisolone. A significant decrease of the mean dose of oral GCs was observed between baseline and the last follow-up visit (4.65 ± 3.69 mg) (p = 0.003). TCZ treatment significantly decreased erythrocyte sedimentation rate (p < 0.01) and CRP levels (p < 0.01). At follow-up (mean 8.18 ± 3.63 months), all patients were in clinical and serological remission. Moreover, PET, CDUS, MRI/MRA, and CTA did not show any LVV finding. CONCLUSIONS: Our study highlights TCZ efficacy in inducing GCA remission and its steroid-sparing effect. We highlighted a reliability of imaging procedures in the evaluation of disease activity and treatment response. A close disease monitoring with imaging techniques should be taken into account in GCA patients during TCZ treatment. Hindawi 2020-09-27 /pmc/articles/PMC7537685/ /pubmed/33061825 http://dx.doi.org/10.1155/2020/3203241 Text en Copyright © 2020 Edoardo Conticini et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Conticini, Edoardo
Sota, Jurgen
Falsetti, Paolo
Baldi, Caterina
Bardelli, Marco
Bellisai, Francesca
Tosi, Gian Marco
Frediani, Bruno
Cantarini, Luca
The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title_full The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title_fullStr The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title_full_unstemmed The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title_short The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
title_sort role of multimodality imaging in monitoring disease activity and therapeutic response to tocilizumab in giant cell arteritis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537685/
https://www.ncbi.nlm.nih.gov/pubmed/33061825
http://dx.doi.org/10.1155/2020/3203241
work_keys_str_mv AT conticiniedoardo theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT sotajurgen theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT falsettipaolo theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT baldicaterina theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT bardellimarco theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT bellisaifrancesca theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT tosigianmarco theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT fredianibruno theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT cantariniluca theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT conticiniedoardo roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT sotajurgen roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT falsettipaolo roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT baldicaterina roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT bardellimarco roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT bellisaifrancesca roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT tosigianmarco roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT fredianibruno roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis
AT cantariniluca roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis